Table 1.
Baseline characteristics of patientsa with and without day 7 lumefantrine concentrations
| Parameter | Patients with day 7 lumefantrine concentration | Patients without day 7 lumefantrine concentration | P valueb | ||
|---|---|---|---|---|---|
| N | Median (range) or N (%) | N | Median (range) or N (%) | ||
| Age (years) | 2,786 | 6.2 (0.3 to 86.7) | 2,805 | 5.5 (0.2 to 80.0) | 0.028 |
| Age category | <0.001 | ||||
| < 1 year | 82 (3.0) | 107 (3.8) | |||
| 1–2 years | 573 (20.6) | 590 (21.0) | |||
| 3–4 years | 615 (22.1) | 604 (21.5) | |||
| 5–11 years | 564 (20.2) | 852 (30.4) | |||
| ≥ 12 years | 953 (34.2) | 652 (23.2) | |||
| Weight (kg) | 2,786 | 18.5 (5.0 to 150.0) | 2,797 | 17.0 (5.0 to 97.0) | 0.104 |
| Underweightc | 1,269 | 220 (17.3) | 1,299 | 218 (16.8) | 0.211 |
| Total dose (mg/kg) | 2,764 | 65.5 (19.2 to 144.0) | 2,786 | 65.5 (20.9 to 144) | 0.092 |
| Treatment supervision | 2,787 | 2,788 | <0.001 | ||
| Fully | 1,971 (70.7) | 1,644 (59.0) | |||
| Partially | 115 (4.1) | 602 (21.6) | |||
| Unsupervised | 701 (25.2) | 542 (19.4) | |||
| Co-administration with fat | 2,787 | 2,809 | 0.147 | ||
| Yes/advised | 2,204 (79.1) | 1,752 (62.4) | |||
| Not stated | 583 (20.9) | 1,057 (37.6) | |||
| Parasitemia (/μl) | 2,767 | 17,140 (16 to 524,414) | 2,799 | 18,120 (10 to 862,400) | 0.021 |
| Temperature (°C) | 2,662 | 37.7 (34.3 to 41.9) | 1,967 | 37.5 (35.0 to 41.5) | <0.001 |
| Hemoglobin (g/dL) | 2,068 | 10.6 (4.8 to 25) | 1,484 | 11.3 (4.2 to 17.9) | 0.428 |
| Sex (female) | 2,787 | 1,281 (46.0) | 2,805 | 1,278 (45.6) | 0.857 |
| Gametocytes present | 2,418 | 112 (4.9) | 1,654 | 92 (5.6) | 0.797 |
| Moderate anemia | 2,507 | 1,132 (45.1) | 1,484 | 516 (34.8) | 0.016 |
| Severe anemia | 2,507 | 155 (6.2) | 1,484 | 57 (3.8) | 0.056 |
aPatients enrolled in the 21 studies included in the pooled analysis; badjusted for study site in a random effects model; cdefined using a weight-for-age Z-score (WAZ) < −2 in children <5 years of age